Considering the nature of SIRPα-expressing macrophages and dendritic cells as professional antigen-presenting cells [88, 89], concurrently activating both innate immune cells via CD47-SIRPα blockade and adaptive immune cells via immune checkpoint inhibitors in conjunction with other tumor-targeted therapies so to achieve long-lasting anti-tumor activity would be the future of drug development for tumor immunotherapy. The gene discussed is SIRPA; the disease is neoplasm.